Condition

Hematological Malignancy (2)

Blood Cancer (1)

Diffuse Large B Cell Lymphoma (1)

Leukemia, Lymphocytic, Chronic, B-Cell (1)

Non-Hodgkin's B-cell Lymphoma (1)

Small Lymphocytic Leukemia (1)

Overall Status

Completed (1)

Terminated (1)

Sign in for free

Phase

phase 1 (1)

phase 1/phase 2 (1)

Sponsor

Astellas Pharma Global Development, Inc. (1)

Molecular Templates, Inc. (1)

Collaborator

Basilea Pharmaceutica International Ltd (1)

Intervention

isavuconazonium sulfate - intravenous (1)

isavuconazonium sulfate - oral (1)

mt-3724 phase 1 (1)

mt-3724 phase 2 (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (2)

Study Type

Interventional (2)

Hematological Malignancy

Showing NaN - NaN of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Leukemia Trial in Worldwide (MT-3724

Terminated

Has Results

Non-Hodgkin's B-cell Lymphoma
+5 more

MT-3724 Phase 1
MT-3724 Phase 2

Tucson, Arizona
+40 more

Jul 18, 2022

Hematological Malignancy Trial in United States (isavuconazonium sulfate - intravenous, isavuconazonium sulfate - oral)

Completed

Hematological Malignancy

isavuconazonium sulfate - intravenous
isavuconazonium sulfate - oral

Long Beach, California
+15 more

Jun 30, 2020